share_log

CRISPR Therapeutics | DEFA14A: Others

CRISPR Therapeutics | DEFA14A: Others

CRISPR Therapeutics | DEFA14A：其他
SEC announcement ·  04/10 04:46
牛牛AI助理已提取核心訊息
CRISPR Therapeutics AG, a company listed on the US stock exchange under the ticker CRSP.US, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC). This filing is part of the Schedule 14A, which is a proxy statement required by Section 14(a) of the Securities Exchange Act of 1934. The document indicates that CRISPR Therapeutics is the registrant and there are no other parties filing the proxy statement. The company has confirmed that no filing fee is required for this submission.
CRISPR Therapeutics AG, a company listed on the US stock exchange under the ticker CRSP.US, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC). This filing is part of the Schedule 14A, which is a proxy statement required by Section 14(a) of the Securities Exchange Act of 1934. The document indicates that CRISPR Therapeutics is the registrant and there are no other parties filing the proxy statement. The company has confirmed that no filing fee is required for this submission.
在美國證券交易所上市的股票代碼爲CRSP.US的公司CRISPR Therapeutics AG已向美國證券交易委員會（SEC）提交了明確的額外材料。該文件是附表14A的一部分，附表14A是1934年《證券交易法》第14（a）條要求的代理聲明。該文件表明，CRISPR Therapeutics是註冊人，沒有其他各方提交委託書。該公司已確認本次提交不需要任何申請費。
在美國證券交易所上市的股票代碼爲CRSP.US的公司CRISPR Therapeutics AG已向美國證券交易委員會（SEC）提交了明確的額外材料。該文件是附表14A的一部分，附表14A是1934年《證券交易法》第14（a）條要求的代理聲明。該文件表明，CRISPR Therapeutics是註冊人，沒有其他各方提交委託書。該公司已確認本次提交不需要任何申請費。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。